GlycoMar has set out to be an early stage drug discovery company. The Company aims to be the world's premier supplier of marine glycobiology compounds to the biopharmaceutical industry. The Company's objectives are the isolation, characterisation and screening of marine glycobiology products in order to identify lead compounds. The Company is currently focussed on identifying new anti-inflammatory leads, which it hopes to offer for licensing in the near future.
